US EditionContivue Port Delivery Platform for nAMD Receives CE Mark
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.5 Articles
5 Articles
Roche Receives CE Mark for Contivue Port Delivery Platform with Susvimo in Wet AMD
The European Union (EU) has granted the CE mark for Roche's Port Delivery Platform containing Susvimo, which will be branded as Contivue in the EU. Contivue provides sustained ocular drug delivery for patients living with wet age-related macular degeneration (AMD). The Contivue platform consists of an ocular implant and four ancillary devices designed for implant filling, surgical insertion, in-office refill-exchange, and, if required, implant r…
Roche wins CE mark for Contivue drug-eluting eye implant
Roche announced today that it received CE mark approval for its port delivery platform containing its Susvimo therapeutic. The device, known as Contivue in Europe, comprises the eye implant through which Susvimo is delivered, plus four ancillary devices to initially fill, insert, refill and remove the implant if required. Susvimo (ranibizumab injection) 100 mg/mL remains under review in Europe for the treatment of neovascular age-related macular…
Roche has announced that it has received the CE mark from the EU for its platform of ocular administration with 'Susvimo', that in Europe it will be called 'Contivue' and that it treats macular degeneration associated with the neovascular age (DMAEn).
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
